T. Rowe Price Associates, Inc. 13D and 13G filings for Entrada Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 1:22 pm Purchase |
2024-09-30 | 13G | Entrada Therapeutics, Inc. TRDA |
T. Rowe Price Associates, Inc. | 3,049,572 8.200% |
39,899 (+1.33%) |
Filing |
| 2024-02-14 10:03 am Sale |
2023-12-31 | 13G | Entrada Therapeutics, Inc. TRDA |
T. Rowe Price Associates, Inc. | 3,009,673 9.000% |
-4,704 (-0.16%) |
Filing |
| 2023-02-14 12:38 pm Purchase |
2022-12-31 | 13G | Entrada Therapeutics, Inc. TRDA |
T. Rowe Price Associates, Inc. | 3,014,377 9.600% |
993,740 (+49.18%) |
Filing |
| 2022-02-14 2:35 pm Purchase |
2021-12-31 | 13G | Entrada Therapeutics, Inc. TRDA |
T. Rowe Price Associates, Inc. | 2,020,637 6.400% |
2,020,637 (New Position) |
Filing |